Teopiz KM

Cognitive effects of ketamine and esketamine treatment for major depressive and bipolar disorder: a systematic review.

Xiao K, Woo Y, Dri CE +12

ArticleMDMA

The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression.

Le GH, Wong S, Johnson DE +6

Are the current safety measures for the treatment of depression with esketamine sufficient?

Valentino K, Teopiz KM, Dri CE +3

The use of repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), ketamine, and esketamine in reducing suicidality in major depressive disorder: A comprehensive narrative review.

Menon T, Lu A, Arulmozhi A +7

The effect of glutamatergic modulators on sleep behavior and architecture in depressive disorders: A systematic review.

Valentino K, Ballum H, Cheung W +11

Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression.

Kaczmarek ES, Rodrigues NB, Chisamore N +8

Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease.

Xu T, Wong S, Le GH +9

The effect of dextromethorphan on reward-related behaviors: A systematic review of preclinical and clinical evidence.

Teopiz KM, Le GH, Wong S +1

Effects of Intravenous Ketamine on Posttraumatic Stress Disorder (PTSD): A Systematic Review.

Yin L, Lu A, Le GH +13

The effects of ketamine and esketamine on functional outcomes in major depressive disorder and treatment-resistant depression: A systematic review.

Ji IS, Cheng MCH, Teopiz KM +8

A Global Population-Based Study on the Association Between Ketamine and Esketamine With Suicidality Using WHO VigiBase.

Kwan ATH, Lakhani M, Rosenblat JD +8

Should glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? Conceptual and clinical implications.

Teopiz KM, Lo HKY, Lakhani M +11

The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review.

Cheng MCH, Dri CE, Ballum H +5

Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis.

Kwan ATH, Lakhani M, Teopiz KM +8

The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS).

McIntyre RS, Mansur RB, Rosenblat JD +2

The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).

Kwan ATH, Rosenblat JD, Mansur RB +2

Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis.

Calder CN, Kwan ATH, Teopiz KM +7

Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.

Le GH, Wong S, Badulescu S +11

Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023.

Havlik JL, Wahid S, Teopiz KM +3

A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.

Wong S, Kwan ATH, Teopiz KM +8

A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.

Pouyan N, Halvaei Khankahdani Z, Younesi Sisi F +14

Europe PMC2022

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.

Ling S, Ceban F, Lui LMW +12

Europe PMC2022